CGM improves glucose control in type 1 diabetes – No 78

Web Version

Forward

TABLE OF CONTENTS

•

CGM improves glucose control in type 1 diabetes

•

Suliqua approved in Europe for adults with type 2 diabetes

•

Green light for new two-drug therapy from AstraZeneca

•

New safer insulin prescribing summary

•

Long-term benefits of diabetes intervention programme demonstrated

DO YOU HAVE A STORY TO TELL?

GET IN TOUCH

Email your diabetes stories to editor Oliver Jelley.

DSN Spotlight – Anna Vanderpuye

Diabetes Specialist Nurse Anna Vanderpuye has been using her annual leave to hold diabetes prevention programmes in Ghana since 2007.

Here, she has her say on what needs to change in diabetes care around the world. To read more, click here.

Join the expanding diabetes community on Twitter and follow us for the latest diabetes news updates at @DiabetesTimes.

On the horizon – Dr Partha Kar’s latest blog post

Let's try something positive in this blog, shall we? It's a tough ask, and when you relate to the NHS, it's doubly tough. If I criticise something within the NHS nowadays, I get "how could you do that as an NHS England bod?"

Whilst lauded by some for being "transparent"… while the same folks turn on you for being positive, "how could you say it's not all bad when the NHS is on the verge of utter obliteration?"

In the cold light of day, Trump did actually win, simply by eliminating from our lives balance or a rational debate.

Anyway, let's try to write something positive, something related to the job I do with NHS England. To read more, click here.

Evaluation of type 2 diabetes lifestyle programme for women

Researchers are evaluating a structured lifestyle programme for women with type 2 diabetes.

To read more, click here.

Diabetes jobs page

We have re-launched our jobs page for healthcare professionals working in diabetes. To visit the page, click here.

CGM improves glucose control in type 1 diabetes

The use of continuous glucose monitoring (CGM) leads to a greater decrease in HbA1c levels compared with usual care, according to a new study.

The DIaMonD study (Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes) was the first of its kind as it demonstrated the impact of CGM on HbA1C and hypoglycaemia in adults with type 1 diabetes on a multiple daily injection insulin regimen. To read more, click here.

Suliqua approved in Europe for adults with type 2 diabetes

Sanofi’s new insulin and GLP-1 combination Suliqua has received marketing approval from the European Commission.

The once-daily treatment combines Lantus (insulin glargine) with Lyxumia (lixisenatide) and is authorised for use in combination with metformin to improve glycaemic control as a further treatment option. To read more, click here.

Green light for new two-drug therapy from AstraZeneca

AstraZeneca’s two-drug therapy for type 2 diabetes Qtern (saxagliptin and dapagliflozin fixed-dose combination) is now available in the UK for adults.

Saxagliptin and dapagliflozin fixed-dose combination (saxa/dapa FDC) is a once-daily tablet that combines saxagliptin 5mg, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with dapagliflozin 10mg, a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

To read more, click here.

New safer insulin prescribing summary

NICE has published new advice about prescribing insulin to support improved clinical practice.

The online resource called ‘Safer insulin prescribing’ summarises the evidence base in the therapeutic area to supporting the medicine's optimisationn, but is not formal NICE guidance.

To read more, cllck here.

Long-term benefits of diabetes intervention programme demonstrated

The long-term impact of an intensive lifestyle intervention on cardiovascular risk factors in people with type 2 diabetes has been proven in real-world clinical practice.

Results from a follow-up study of obese people with type 2 diabetes, who lost at least seven per cent of their body weight after one year of an intensive lifestyle intervention, show that those who sustained their weight loss maintained most of its benefits on HbA1c and cholesterol for five years.

To read more, click here.

DIABETES DIGEST

Diabetes technology fellowship in South East

Applications are being sought for a project to improve access to medical technology for adults with type 1 diabetes.

The role, a Darzi Fellowship, will involve working with secondary care diabetes teams across Kent, Surrey and Sussex to improve diabetes services and access to insulin pump therapy and continuous glucose monitoring devices.

To read more, click here.

Nocturnal hypo effects of analogue and human insulins compared

Treatment with insulin analogue reduces nocturnal hypoglycaemia in people with type 1 diabetes prone to severe hypoglycaemia, research has found.

The finding was based on assessing nocturnal glucose profiles to provide a more comprehensive assessment of clinical benefit of insulin regimens compared to conventional recording of hypoglycaemia. To read more, click here.

Type 2 medicine label to include cardiovascular death reduction data

The type 2 drug Jardiance (empagliflozin) has become the first medication in the European Union to include cardiovascular death reduction data on the label. To read more, click here.

Regional type 2 diabetes prevention week launched

A campaign to raise awareness of a national drive to prevent type 2 diabetes has taken place across the East Midlands.

Diabetes Prevention Week – which started on Monday, January, 16 – has been developed to raise awareness of type 2 diabetes and increase referral numbers onto the Healthier You: NHS Diabetes Prevention Programme. To read more, click here.

The Diabetes Manager – Above and beyond

Abigail Kitt's latest blog post as The Diabetes Manager.

The submission deadline for the Diabetes Transformation Fund is today at 5pm. To read more, click here.

Views sought on new Type 1 diabetes model

People with type 1 diabetes have been invited to a meeting to help develop a new ‘whole person’ model of care for the condition. To read more, click here.